Market Cap 7.53M
Revenue (ttm) 0.00
Net Income (ttm) -7.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 57,200
Avg Vol 132,840
Day's Range N/A - N/A
Shares Out 5.56M
Stochastic %K 27%
Beta -2.02
Analysts Strong Sell
Price Target $17.00

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 533 1469
Address:
259 Liberty Avenue, Staten Island, United States
Porcavacca
Porcavacca Sep. 14 at 10:47 PM
$ACXP any rumors? Tell me. Investor from Italy
0 · Reply
Christa3
Christa3 Sep. 14 at 6:51 PM
$ACXP https://www.acurxpharma.com/news-media/press-releases/detail/143/acurx-announces-presentation-of-a-scientific-poster-at-the
0 · Reply
Twinter11
Twinter11 Sep. 12 at 12:29 AM
$SONA.CSE $RAPH $APTN $ACXP $CYDY Thanks! At first I thought you were spamming lol. How did you know about it? Are you involved and I wonder who is presenting for cydy. I only saw they were a presenting company.
2 · Reply
B2iDigital
B2iDigital Sep. 11 at 7:53 PM
Thursday, September 17: The Life Sciences Virtual Investor Forum, live online, hosted by Virtual Investor Conferences. Oncology. Fibrosis. Drug delivery. Antibiotics. Cannabinoid therapeutics. Respiratory imaging. Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind. A B2i Digital Featured Conference. Event details and profiles of presenting companies: https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum Scheduled to present (subject to change): 11:00 AM ET: Sona Nanotech Inc. (OTCQB: SNANF | CSE: $SONA.CSE ) 11:30 AM ET: Raphael Pharmaceutical (OTCQB: $RAPH ) 2:00 PM ET: Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX) 2:30 PM ET: Adaptin Bio, Inc. (OTCQB: $APTN ) 3:00 PM ET: Acurx Pharmaceuticals, Inc. (Nasdaq: $ACXP) 3:30 PM ET: CytoDyn Inc. (OTCQB: $CYDY ) 4:00 PM ET: 4DMedical Ltd. (OTC: FDMDF | ASX: 4DX) Can't watch live? Replays go up on the B2i Digital and OTC Markets YouTube channels. Register: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC To request one-on-one meetings with management: https://app.axleaccess.com/public/events/019cf1e8-5723-46bd-8ded-5b7a610d6f8e?token=85aa08be-2ca5-442e-b15f-88291e58a98a B2i Digital, The Capital Markets Matchmaker℠, carries each presenting company's story From Marketing to Meetings℠ across its media network with a 330 million+ combined monthly audience and its own community of 1.7 million+ investors and market participants. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
2 · Reply
finallyfree33
finallyfree33 Sep. 11 at 6:35 PM
$ACXP This is an easy double your money type of play💵⬆️
0 · Reply
Christa3
Christa3 Sep. 1 at 3:25 PM
$ACXP recent Luci interview https://youtu.be/xu1DIhWUQrg?si=ns0dZZsQEYSIYqDY
1 · Reply
NotBornYesterday
NotBornYesterday Sep. 1 at 1:08 PM
$ACXP 27 https://www.congress.gov/bill/119th-congress/house-bill/7352/cosponsors?pageSort=lastToFirst&loclr=cga-bill
0 · Reply
Christa3
Christa3 Aug. 19 at 11:45 PM
$ACXP https://clinicaltrials.gov/study/NCT07513285?term=Acurx&viewType=Card&rank=2#locations
0 · Reply
Christa3
Christa3 Aug. 19 at 6:35 PM
$ACXP CIFBEZY doesn’t just kill C. diff — Phase 2 data showed it also helps restore healthy bile acid balance in the gut. That’s a big deal because the right bile acids help stop recurrence. Another reason this one looks different from the usual antibiotics. Acurx is nano-cap, beaten-down, trading near all time lows. Low float means you can actually own a significant portion of the company for cheap. Having seen a relative suffer from recurrent C. diff until the day he died, I found this company and have been buying for months as I’m learning more about the science behind their pipeline. There is a need for novel antibiotics.
2 · Reply
Christa3
Christa3 Aug. 19 at 6:24 PM
$ACXP New antibiotic for C. diff (CIFBEZY). Phase 2a: 100% cure. Overall Phase 2: 96% cure with zero recurrences in cured patients. Microbiome-friendly. FDA just accepted the brand name. They also have a smart dual path: small PATHFINDER trial in recurrent patients could open an LPAD route — potentially one cheaper Phase 3 instead of the bigger program.
0 · Reply
Latest News on ACXP
Acurx Pharmaceuticals Proxy statement: Proxy filing

Sep 1, 2026, 8:00 AM EDT - 15 days ago

Acurx Pharmaceuticals Proxy statement: Proxy filing


Acurx Pharmaceuticals Proxy statement: Proxy filing

Sep 1, 2026, 8:00 AM EDT - 15 days ago

Acurx Pharmaceuticals Proxy statement: Proxy filing


Acurx Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 14, 2026, 8:00 AM EDT - 4 weeks ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2026


Acurx Pharmaceuticals Quarterly report: Q2 2026

Aug 14, 2026, 8:00 AM EDT - 4 weeks ago

Acurx Pharmaceuticals Quarterly report: Q2 2026


Acurx Pharmaceuticals Earnings release: Q2 2026

Aug 14, 2026, 8:00 AM EDT - 4 weeks ago

Acurx Pharmaceuticals Earnings release: Q2 2026


Acurx’s ibezapolstat shows microbe preservation efficacy

2026-07-14T12:10:22.000Z - 2 months ago

Acurx’s ibezapolstat shows microbe preservation efficacy


Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026


Acurx Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals Quarterly report: Q1 2026


Acurx Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals Earnings release: Q1 2026


Acurx files to sell 1.65M shares of common stock for holders

2026-05-04T20:30:19.000Z - 4 months ago

Acurx files to sell 1.65M shares of common stock for holders


Acurx files to sell 1.3M shares of common stock for holders

2026-05-04T20:29:36.000Z - 4 months ago

Acurx files to sell 1.3M shares of common stock for holders


New to The Street announce re-signing of Acurx Pharmaceuticals

2026-04-07T13:33:21.000Z - 5 months ago

New to The Street announce re-signing of Acurx Pharmaceuticals


Acurx price target lowered to $10 from $20 at Alliance Global

2026-03-13T16:50:20.000Z - 6 months ago

Acurx price target lowered to $10 from $20 at Alliance Global


Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025


Acurx Pharmaceuticals Earnings release: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Acurx Pharmaceuticals Earnings release: Q4 2025


Acurx Pharmaceuticals Annual report: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Acurx Pharmaceuticals Annual report: Q4 2025


Acurx announces new ibezapolstat clinical trial program

2026-03-09T12:05:07.000Z - 6 months ago

Acurx announces new ibezapolstat clinical trial program


Acurx files to sell 750,000 shares of common stock for holders

2026-02-02T21:50:10.000Z - 7 months ago

Acurx files to sell 750,000 shares of common stock for holders


Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025


Acurx Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals Earnings release: Q3 2025


Acurx Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals Quarterly report: Q3 2025


Acurx Pharmaceuticals Registration statement: Registration Filing

Oct 20, 2025, 8:00 AM EDT - 11 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing


Acurx Pharmaceuticals Slides: Conference presentation

Oct 20, 2025, 7:00 AM EDT - 11 months ago

Acurx Pharmaceuticals Slides: Conference presentation


Acurx Pharmaceuticals Slides: Study update presentation

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Slides: Study update presentation


Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025


Acurx Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q2 2025


Acurx Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q2 2025


Acurx Pharmaceuticals Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 31, 2025, 9:25 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split


Acurx Pharmaceuticals Proxy statement: Proxy Filing

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025


Acurx Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q1 2025


Acurx Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q1 2025


Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024


Acurx Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q4 2024


Acurx Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Annual report: Q4 2024


Porcavacca
Porcavacca Sep. 14 at 10:47 PM
$ACXP any rumors? Tell me. Investor from Italy
0 · Reply
Christa3
Christa3 Sep. 14 at 6:51 PM
$ACXP https://www.acurxpharma.com/news-media/press-releases/detail/143/acurx-announces-presentation-of-a-scientific-poster-at-the
0 · Reply
Twinter11
Twinter11 Sep. 12 at 12:29 AM
$SONA.CSE $RAPH $APTN $ACXP $CYDY Thanks! At first I thought you were spamming lol. How did you know about it? Are you involved and I wonder who is presenting for cydy. I only saw they were a presenting company.
2 · Reply
B2iDigital
B2iDigital Sep. 11 at 7:53 PM
Thursday, September 17: The Life Sciences Virtual Investor Forum, live online, hosted by Virtual Investor Conferences. Oncology. Fibrosis. Drug delivery. Antibiotics. Cannabinoid therapeutics. Respiratory imaging. Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind. A B2i Digital Featured Conference. Event details and profiles of presenting companies: https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum Scheduled to present (subject to change): 11:00 AM ET: Sona Nanotech Inc. (OTCQB: SNANF | CSE: $SONA.CSE ) 11:30 AM ET: Raphael Pharmaceutical (OTCQB: $RAPH ) 2:00 PM ET: Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX) 2:30 PM ET: Adaptin Bio, Inc. (OTCQB: $APTN ) 3:00 PM ET: Acurx Pharmaceuticals, Inc. (Nasdaq: $ACXP) 3:30 PM ET: CytoDyn Inc. (OTCQB: $CYDY ) 4:00 PM ET: 4DMedical Ltd. (OTC: FDMDF | ASX: 4DX) Can't watch live? Replays go up on the B2i Digital and OTC Markets YouTube channels. Register: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC To request one-on-one meetings with management: https://app.axleaccess.com/public/events/019cf1e8-5723-46bd-8ded-5b7a610d6f8e?token=85aa08be-2ca5-442e-b15f-88291e58a98a B2i Digital, The Capital Markets Matchmaker℠, carries each presenting company's story From Marketing to Meetings℠ across its media network with a 330 million+ combined monthly audience and its own community of 1.7 million+ investors and market participants. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
2 · Reply
finallyfree33
finallyfree33 Sep. 11 at 6:35 PM
$ACXP This is an easy double your money type of play💵⬆️
0 · Reply
Christa3
Christa3 Sep. 1 at 3:25 PM
$ACXP recent Luci interview https://youtu.be/xu1DIhWUQrg?si=ns0dZZsQEYSIYqDY
1 · Reply
NotBornYesterday
NotBornYesterday Sep. 1 at 1:08 PM
$ACXP 27 https://www.congress.gov/bill/119th-congress/house-bill/7352/cosponsors?pageSort=lastToFirst&loclr=cga-bill
0 · Reply
Christa3
Christa3 Aug. 19 at 11:45 PM
$ACXP https://clinicaltrials.gov/study/NCT07513285?term=Acurx&viewType=Card&rank=2#locations
0 · Reply
Christa3
Christa3 Aug. 19 at 6:35 PM
$ACXP CIFBEZY doesn’t just kill C. diff — Phase 2 data showed it also helps restore healthy bile acid balance in the gut. That’s a big deal because the right bile acids help stop recurrence. Another reason this one looks different from the usual antibiotics. Acurx is nano-cap, beaten-down, trading near all time lows. Low float means you can actually own a significant portion of the company for cheap. Having seen a relative suffer from recurrent C. diff until the day he died, I found this company and have been buying for months as I’m learning more about the science behind their pipeline. There is a need for novel antibiotics.
2 · Reply
Christa3
Christa3 Aug. 19 at 6:24 PM
$ACXP New antibiotic for C. diff (CIFBEZY). Phase 2a: 100% cure. Overall Phase 2: 96% cure with zero recurrences in cured patients. Microbiome-friendly. FDA just accepted the brand name. They also have a smart dual path: small PATHFINDER trial in recurrent patients could open an LPAD route — potentially one cheaper Phase 3 instead of the bigger program.
0 · Reply
flcountryboy
flcountryboy Aug. 18 at 4:29 PM
$ACXP Thoughts on expected dilution?
3 · Reply
STACKD0E
STACKD0E Aug. 17 at 2:50 PM
$ACXP 🙃✨
0 · Reply
RTPRwire
RTPRwire Aug. 17 at 2:42 PM
$ACXP is seeing a strong reaction on clinical trial results following a PR Newswire release. Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat RTPR pushed this release out to users at 8:01:00 AM ET
0 · Reply
ballyhooo
ballyhooo Aug. 17 at 2:06 PM
$ACXP we got a name now how about an approval!
0 · Reply
focafoca99
focafoca99 Aug. 17 at 12:34 PM
$ACXP obtained FDA conditional acceptance and USPTO trademark allowance for its CIFBEZY brand name.
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 17 at 12:04 PM
$ACXP Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 14 at 5:52 PM
ACXP Q2 2026 Earnings Summary $ACXP https://stocktwits.com/news/earnings/ai summaries/acxp-q2-2026-earnings-summary/cZotYgmRJ0s
0 · Reply
Cpictures
Cpictures Aug. 14 at 2:47 PM
$ACXP Friendly reminder that this is not a real company. There are no research labs or offices - it is a couple of old guys with a patent "working" from home. There will be no phase 3 trial. Their "product" is stock offerings which goes to fund the salaries of said old men. They will keep the game going until it is delisted.
0 · Reply
Agge11
Agge11 Aug. 14 at 1:29 PM
0 · Reply
Agge11
Agge11 Aug. 14 at 1:29 PM
$ACXP 10 $ today 🚀🚀🚀🚀💪
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 14 at 1:04 PM
$ACXP Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.53 up 71.96% YoY
0 · Reply
focafoca99
focafoca99 Aug. 14 at 11:13 AM
$ACXP is reporting Q2 2026 results, closing a $2.5M direct offering and ending the quarter with $10.7M cash.
0 · Reply